| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 7389457 | Value in Health | 2017 | 4 Pages |
Abstract
The risk of HF needs to be taken into account when prescribing DPP-4 inhibitors. Evidence suggests that vildagliptin may be the least harmful agent with regard to the risk of HF. However, a statistically significant inconsistency was identified in the Bayesian network meta-analysis. Therefore, further studies are warranted to evaluate the cardiovascular safety of DPP-4 inhibitors.
Related Topics
Health Sciences
Medicine and Dentistry
Medicine and Dentistry (General)
Authors
Wen-Qin MD, Lang PhD, Qiang PhD, Wei-Ran MD, Zi-Liang MD,